Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Tokyo  >  Takeda Pharmaceutical Co Ltd    4502   JP3463000004

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Takeda Pharmaceutical : Supports Launch of Five-Year, $1M Initiative Spearheaded by the Massachusetts Life Sciences Center to Back Women-Driven Early Stage Companies

share with twitter share with LinkedIn share with facebook
share via e-mail
11/10/2017 | 08:16pm CEST

Competitive Program to Award Two Recipients Annually with Funding and Mentorship –

Takeda Pharmaceutical Company Limited (TSE:4502) today announced its support of the launch of the MassNextGen initiative, a five-year, $1M program anchored by Takeda and matched by the Massachusetts Life Sciences Center (MLSC), to support women-led or controlled early-stage biotech companies. This highly competitive program aims to provide a year-long customized package of support that includes funding and executive coaching. The announcement was made today at Takeda Boston, which included Massachusetts Governor Charles Baker.

“Despite being essential members of the life sciences industry, women continue to be underrepresented, including at the executive level in which there remains a large gender gap,” said Christophe Bianchi M.D., President, Takeda Global Oncology Business Unit, Takeda Boston Site Head. “As an organization committed to diversity and inclusion, our contributions to the MassNextGen program and collaboration with the Massachusetts Life Sciences Center will further elevate the innovations that are being created by women-led companies, which have strong potential to make a difference in the future of our industry and the lives of patients.”

“The strength of startup life sciences companies is critical to Massachusetts innovation economy and we are committed to building diversity and empowering more women entrepreneurs in this growing field,” said Governor Charlie Baker. “This initiative will help more women-led companies to thrive, leveraging additional sources of capital and support to create new jobs and bring cutting edge innovation to the marketplace.”

“We are thrilled to begin this initiative with a strong partner in Takeda, and we look forward to collaborating with more companies, organizations and leaders to tackle this important issue,” said Lt. Governor Karyn Polito. “Through STEM-training initiatives and private sector partnerships like these, our administration is committed to increasing the representation of women in the life sciences.”

Each year, beginning in January 2018, a panel of judges comprised of representatives from MLSC, Takeda and the Executive Coaching network will select two women-owned/controlled early-stage companies to receive a year-long customized package of support through the MassNextGen program. The criteria used to determine winners will include level of involvement of women in the conception, strategy and execution of the company, the proposed use of the funds and the business plan feasibility. Each customized package will include both funding and access to a network of executive coaches that will help support, advise, and mentor the recipients.

Proposals for the first year of the program are due in February. For more information about the MassNextGen program, please visit: www.masslifesciences.com/programs/massnextgen.

About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.

Additional information about Takeda is available through its corporate website, www.takeda.com, and additional information about Takeda Oncology, the brand for the global oncology business unit of Takeda Pharmaceutical Company Limited, is available through its website, www.takedaoncology.com.

© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
10/12TAKEDA PHARMACEUTICAL : Earnings Conference for the 2nd Quarter of Fiscal Year 2..
10/06SHIRE : Disgruntled Takeda alumni demand a window into $62B Shire buy
10/04SEATTLE GENETICS : and Takeda Announce Positive Results from Phase 3 ECHELON-2 C..
10/04SEATTLE GENETICS` : Adcetris tops chemo in Phase 3 lymphoma trial
10/02TAKEDA PHARMACEUTICAL : Working Mother Names Takeda as One of the 2018 '100 Best..
10/02TAKEDA PHARMACEUTICAL : and Lundbeck Submit New Drug Application for Vortioxetin..
10/02SHIRE : Takeda Establishes Record Date for the Extraordinary General Meeting of ..
10/01TAKEDA PHARMACEUTICAL : Seattle Genetics and Takeda Announce Positive Results fr..
09/28TAKEDA PHARMACEUTICAL : $62 billion Shire bid faces November 6 EU antitrust dead..
09/28TAKEDA PHARMACEUTICAL : $62 billion Shire bid faces Nov. 6 EU antitrust deadline
More news
News from SeekingAlpha
10/15FDA issues new guidance aimed at more efficient drug development 
10/13STOCKS TO WATCH : Was That A Speed Bump? 
10/11European Commission assessment of Takeda/Shire tie-up continues 
10/08Merger Arbitrage Mondays - October 8, 2018 
10/08Takeda Pharmaceuticals presents data analyses for Entyvio in bio-naïve patien.. 
Financials (JPY)
Sales 2019 1 765 B
EBIT 2019 -
Net income 2019 162 B
Debt 2019 680 B
Yield 2019 4,09%
P/E ratio 2019 21,24
P/E ratio 2020 17,51
EV / Sales 2019 2,37x
EV / Sales 2020 2,22x
Capitalization 3 501 B
Duration : Period :
Takeda Pharmaceutical Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL CO L
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 6 267  JPY
Spread / Average Target 42%
EPS Revisions
Christophe Weber President, CEO & Representative Director
Costa Saroukos Chief Financial Officer
Andrew S. Plump Director, Chief Medical & Scientific Officer
Yasuhiko Yamanaka Managing Director & Head-Globalization
Masato Iwasaki Director & President-Japan Pharma Business Unit
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-4.13%359 060
PFIZER19.05%250 957
NOVARTIS-0.49%211 413
ROCHE HOLDING LTD.-4.44%204 875
MERCK AND COMPANY23.44%181 832